The COVID-19 crisis has strengthened US leadership in the life sciences sector. It is more necessary than ever for European biotechs to get a foothold there, to raise funds, conduct clinical developments and find industrial and commercial partners.
Are the innovation dyamics, FDA approvals and financing (private and listed) sustainable? What has the COVID crisis changed and could change again? How do American investors and industrialists perceive French biotechs? How to succeed in the US (while remaining a French company)? During this round-table we will discuss the trends at work on the other side of the Atlantic, particularly in the biotech and medtech sectors. And our participants will share their own experiences as entrepreneurs and investors.
Relive the event
We'd love to get to know you
Join us, we offer you an extraordinary chance to learn, to develop and to be part of an exciting experience and team.Tell us your story